Errata

In the article “Assessment of Tumoricidal Efficacy and Response to Treatment with ¹⁸F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor,” by Liapi et al. (J Nucl Med. 2011;52:225–230), there was a typographic error in one of the grants mentioned in the “Acknowledgments” section. The study was supported by NIH/NCI grant RO1 CA100883-01, not CA100882-01. The authors regret the error.

In the article “Radioimmunotherapy with ¹⁷⁷Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas,” by Forrer et al. (J Nucl Med. 2013;54:1045–1052), there was an error in the reported mean doses to the 20 patients. The correct whole-body dose is 0.32 mGy/MBq, and the correct absorbed dose to the red marrow is 0.36 mGy/MBq. The authors regret the error.

In Table 1 of “The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0,” by Maurer et al. (J Nucl Med. 2013;54:2004–2013), administered activity was incorrectly given in units of MBq/kg (mCi/kg) instead of MBq (mCi). The authors regret the error.